Meeting
2023 ASCO Genitourinary Cancers Symposium
Angelica herbal supplement AGN-CognI.Q acute dose safety and pharmacokinetics (PK) dose-response in patients with prostate cancer (PK Dose Trial).
Authors
Monika Joshi
Penn State Cancer Institute, Hershey, PA
Monika Joshi , Jay D. Raman , Xin Liu , Doris Shank , Todd D. Schell , Jiangang Jason Liao , Junxuan Lu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Clinical Trial Registration Number
Clinical trial registration NCT05375539
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr TPS404)
DOI
10.1200/JCO.2023.41.6_suppl.TPS404
Abstract #
TPS404
Poster Bd #
R8
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
![EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies.](https://d201v5jt9ylckg.cloudfront.net/316/15821/233888/233888_A322_poster_pv.jpg)
EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies.
First Author: Thomas Lillie
Poster
2018 ASCO Annual Meeting
Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.
First Author: Mark N. Stein
Poster
2018 ASCO Annual Meeting
The GATTO study: A phase I of the anti-MUC1 Gatipotuzumab (GAT) in combination with the anti-EGFR Tomuzotuximab (TO) in patients with EGFR positive solid tumors.
First Author: Sebastian Ochsenreither
Poster
2015 Genitourinary Cancers Symposium
Phase 1/2a, open-label, dose-escalation and safety study of APC-100 in men with advanced prostate cancer.
First Author: Christos Kyriakopoulos